Terfenadine effect on the bronchoconstriction, dermal response, and leukopenia induced by platelet-activating factor

R. J. Hopp, R. G. Townley, Devendra K. Agrawal, Againdra K. Bewtra

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We have investigated the protective effect of oral terfenadine, a H1 antagonist, on the dermal and pulmonary response, and changes of circulating WBCs to injected and inhaled platelet activating factor. Nine men with mild asthma participated in a double-blind, crossover study using terfenadine, 120 mg, or placebo. Three hours after administration of study drug, pulmonary function was measured, and a PAF challenge was performed. Skin test to histamine and PAF was performed prior to study drug, and 2.5 hours after drug. Circulating WBC count was determined prior to PAF inhalation and during the PAF challenge. There was a significant improvement in pulmonary function on terfenadine. Terfenadine significantly inhibited the wheal and flare response to histamine and the flare response to injected PAF. Terfenadine did not have an effect on the change in circulating WBC count or the change in pulmonary function to inhaled PAF. These results suggest a limited role for endogenous histamine for the effects of PAF.

Original languageEnglish
Pages (from-to)994-998
Number of pages5
JournalChest
Volume100
Issue number4
StatePublished - 1991

Fingerprint

Terfenadine
Bronchoconstriction
Platelet Activating Factor
Leukopenia
Skin
Lung
Histamine
Histamine Agents
Pharmaceutical Preparations
Skin Tests
Double-Blind Method
Cross-Over Studies
Inhalation
Asthma
Placebos

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

Terfenadine effect on the bronchoconstriction, dermal response, and leukopenia induced by platelet-activating factor. / Hopp, R. J.; Townley, R. G.; Agrawal, Devendra K.; Bewtra, Againdra K.

In: Chest, Vol. 100, No. 4, 1991, p. 994-998.

Research output: Contribution to journalArticle

@article{d645625486654c398d38ba37416a2ddb,
title = "Terfenadine effect on the bronchoconstriction, dermal response, and leukopenia induced by platelet-activating factor",
abstract = "We have investigated the protective effect of oral terfenadine, a H1 antagonist, on the dermal and pulmonary response, and changes of circulating WBCs to injected and inhaled platelet activating factor. Nine men with mild asthma participated in a double-blind, crossover study using terfenadine, 120 mg, or placebo. Three hours after administration of study drug, pulmonary function was measured, and a PAF challenge was performed. Skin test to histamine and PAF was performed prior to study drug, and 2.5 hours after drug. Circulating WBC count was determined prior to PAF inhalation and during the PAF challenge. There was a significant improvement in pulmonary function on terfenadine. Terfenadine significantly inhibited the wheal and flare response to histamine and the flare response to injected PAF. Terfenadine did not have an effect on the change in circulating WBC count or the change in pulmonary function to inhaled PAF. These results suggest a limited role for endogenous histamine for the effects of PAF.",
author = "Hopp, {R. J.} and Townley, {R. G.} and Agrawal, {Devendra K.} and Bewtra, {Againdra K.}",
year = "1991",
language = "English",
volume = "100",
pages = "994--998",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "4",

}

TY - JOUR

T1 - Terfenadine effect on the bronchoconstriction, dermal response, and leukopenia induced by platelet-activating factor

AU - Hopp, R. J.

AU - Townley, R. G.

AU - Agrawal, Devendra K.

AU - Bewtra, Againdra K.

PY - 1991

Y1 - 1991

N2 - We have investigated the protective effect of oral terfenadine, a H1 antagonist, on the dermal and pulmonary response, and changes of circulating WBCs to injected and inhaled platelet activating factor. Nine men with mild asthma participated in a double-blind, crossover study using terfenadine, 120 mg, or placebo. Three hours after administration of study drug, pulmonary function was measured, and a PAF challenge was performed. Skin test to histamine and PAF was performed prior to study drug, and 2.5 hours after drug. Circulating WBC count was determined prior to PAF inhalation and during the PAF challenge. There was a significant improvement in pulmonary function on terfenadine. Terfenadine significantly inhibited the wheal and flare response to histamine and the flare response to injected PAF. Terfenadine did not have an effect on the change in circulating WBC count or the change in pulmonary function to inhaled PAF. These results suggest a limited role for endogenous histamine for the effects of PAF.

AB - We have investigated the protective effect of oral terfenadine, a H1 antagonist, on the dermal and pulmonary response, and changes of circulating WBCs to injected and inhaled platelet activating factor. Nine men with mild asthma participated in a double-blind, crossover study using terfenadine, 120 mg, or placebo. Three hours after administration of study drug, pulmonary function was measured, and a PAF challenge was performed. Skin test to histamine and PAF was performed prior to study drug, and 2.5 hours after drug. Circulating WBC count was determined prior to PAF inhalation and during the PAF challenge. There was a significant improvement in pulmonary function on terfenadine. Terfenadine significantly inhibited the wheal and flare response to histamine and the flare response to injected PAF. Terfenadine did not have an effect on the change in circulating WBC count or the change in pulmonary function to inhaled PAF. These results suggest a limited role for endogenous histamine for the effects of PAF.

UR - http://www.scopus.com/inward/record.url?scp=0026075986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026075986&partnerID=8YFLogxK

M3 - Article

VL - 100

SP - 994

EP - 998

JO - Chest

JF - Chest

SN - 0012-3692

IS - 4

ER -